TY  - JOUR
AU  - Felip, Enriqueta
AU  - Smit, Egbert F
AU  - Molina-Vila, Miguel A
AU  - Dafni, Urania
AU  - Massuti, Bartomeu
AU  - Berghmans, Thierry
AU  - de Marinis, Filippo
AU  - Passiglia, Francesco
AU  - Dingemans, Anne-Marie C
AU  - Cobo, Manuel
AU  - Viteri, Santiago
AU  - Britschgi, Christian
AU  - Cuffe, Sinead
AU  - Provencio, Mariano
AU  - Merkelbach-Bruse, Sabine
AU  - Andriakopoulou, Charitini
AU  - Kammler, Roswitha
AU  - Ruepp, Barbara
AU  - Roschitzki-Voser, Heidi
AU  - Peters, Solange
AU  - Wolf, Jürgen
AU  - Stahel, Rolf
AU  - ETOP 12-17 ALERT-lung Collaborators
PY  - 2022
DO  - 10.1016/j.lungcan.2022.08.008
UR  - http://hdl.handle.net/10668/22354
T2  - Lung cancer (Amsterdam, Netherlands)
AB  - Alectinib, a highly selective next generation ALK-inhibitor, has exhibited potent anti-tumour activity in RET-rearranged NSCLC in the preclinical stage. ALERT-lung is a single-arm, phase II trial evaluating the activity of alectinib for the treatment...
LA  - en
KW  - Anaplastic Lymphoma Kinase
KW  - Carbazoles
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Female
KW  - Humans
KW  - Lung Neoplasms
KW  - Male
KW  - Middle Aged
KW  - Piperidines
KW  - Protein Kinase Inhibitors
KW  - Proto-Oncogene Proteins c-ret
KW  - Receptor Protein-Tyrosine Kinases
TI  - Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trial.
TY  - research article
VL  - 172
ER  -